سعر ايميتوفويد 1 مجم/مل امبول 2024

Emetovoid 1 mg/ml IV ampoule (granisetron), Sedico, Egypt.

• Prevention and treatment of acute nausea and vomiting associated with chemotherapy and radiotherapy; prevention of delayed CINV/RINV; PONV (adults).Population: Adults; children ≥2 y for acute CINVMHRA/eMC

• Very common: headache, constipation. Common: insomnia, diarrhoea, raised transaminases. Uncommon: hypersensitivity, extrapyramidal reactions, serotonin syndrome, QT prolongation, rash.International label, equivalent formulation · MHRA/eMC

• Hypersensitivity to granisetron or any excipient.International label, equivalent formulation · MHRA/eMC

• May reduce lower bowel motility — monitor if subacute intestinal obstruction. QT prolongation reported with 5-HT3 antagonists; caution in arrhythmia, cardiotoxic chemo, electrolyte abnormalities. Serotonin syndrome risk with SSRIs/SNRIs.International label, equivalent formulation · MHRA/eMC

• QT-prolonging / arrhythmogenic drugsMajorECG changes including QT prolongation; concurrent QT-prolonging or arrhythmogenic drugs may have clinical consequences.MHRA/eMC
• SSRIs / SNRIs (serotonergic drugs)ModerateSerotonin syndrome reported with 5-HT3 antagonists plus serotonergic drugs; observe for serotonin syndrome.MHRA/eMC

• Limited human pregnancy data; animal studies do not indicate reproductive toxicity. Prefer to avoid during pregnancy as a precaution.International label, equivalent formulation · MHRA/eMC
• Unknown whether excreted in human milk; breastfeeding not advised during treatment as a precaution.International label, equivalent formulation · MHRA/eMC

• Granisetron: Selective antagonist of 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone; blocks serotonin-mediated emetic signalling.